ClinicalTrials.gg
CompletedNCT00013897Updated May 4, 2011

A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine

A Phase 3 interventional study of Atazanavir and Lamivudine/Zidovudine in HIV Infections, sponsored by Bristol-Myers Squibb. Completed at 99 sites in 24 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2011-05-04.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies testing lamivudine in HIV Infections — 5 open to participants now, 8 under way, 4 of them phase 3. Lamivudine · HIV Infections.

Started
2001
with 2 others
Phase 3
50 of 132
2 open now
Registered
49th of 132
by date
Lead sponsor
5 of 132
Bristol-Myers Squibb

Among the 132 studies testing lamivudine in HIV Infections, this one is one of 3 that started in 2001, is one of 50 in phase 3, and was the 49th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

5 of the 132 studies testing lamivudine in HIV Infections are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About lamivudine

Lamivudine: first FDA approval 1995 (EPIVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing lamivudine in HIV Infections, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effectiveness of treatment with BMS-232632 to that of efavirenz (EFV) when both are used with zidovudine (ZDV) and lamivudine (3TC).

Read the detailed description

This is a multinational, 2-arm study. Patients in 1 arm receive BMS-232632 plus EFV placebo capsules. Patients in the other arm receive EFV plus BMS-232632 placebo. Both arms also receive a fixed dose of ZDV-3TC.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Placebos
  • Drug Therapy, Combination
  • Zidovudine
  • HIV Protease Inhibitors
  • Lamivudine
  • RNA, Viral
  • Reverse Transcriptase Inhibitors
  • Anti-HIV Agents
  • Viral Load
  • BMS 232632
  • efavirenz
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients may be eligible for this study if they:

  • Have a viral load of 2,000 or more copies/ml and a of 100 or more cells/mm3 (or 75 or more cells/mm3 with no prior history of AIDS-defining diagnosis) within 2 weeks before randomization.
  • Are at least 16 years old.
  • Have signed consent of parent or guardian if under 18 years of age.
  • Are willing to use effective barrier methods of .
  • Are available for follow-up for at least 52 weeks.

Exclusion criteria

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Have had anti- treatment within 30 days before screening.
  • Have a recently diagnosed HIV-related infection.
  • Have any medical condition requiring treatment at enrollment.
  • Have recently become HIV infected.
  • Have acute hepatitis within 30 days of study entry. Certain patients with chronic hepatitis will be eligible.
  • Expect to need or have taken drugs with myelosuppressive, neurotoxic, pancreatotoxic, hepatotoxic, or cytotoxic potential within 3 months before study. Expect to need methadone, ribavirin/interferons, neurotoxic drugs or drugs that affect .
  • Abuse alcohol or drugs.
  • Have severe diarrhea within 30 days before study entry.
  • Are pregnant or breast-feeding.
  • Have a history of hemophilia.
  • Have a history of bilateral peripheral neuropathy.
  • Cannot take medicines by mouth.
  • Have any other conditions that the doctor thinks would interfere with the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Masking
Double

Interventions

06

Study locations

99 sites
  • Phoenix Body Positive
    Phoenix, Arizona 85006, United States
  • Univ of Southern California
    Los Angeles, California 90033, United States
  • Saint Francis Mem Hosp / HIV Care Unit
    San Francisco, California 94109, United States
  • Dupont Circle Physicians Group
    Washington, District of Columbia 200091104, United States
  • Dr Bruce Rashbaum
    Washington, District of Columbia 20037, United States
  • North Broward Hosp District / HIV Clinical Research
    Fort Lauderdale, Florida 33311, United States
  • Associates in Research
    Fort Myers, Florida 33901, United States
  • Steinhart Medical Associates
    Miami, Florida 33133, United States
  • Saint Josephs Comprehensive Research Institute
    Tampa, Florida 33607, United States
  • Emory Univ
    Atlanta, Georgia 30308, United States
  • The CORE Ctr
    Chicago, Illinois 60612, United States
  • Univ of Kansas School of Medicine
    Wichita, Kansas 672143124, United States
  • Univ of Michigan Hospitals and Health Ctrs
    Ann Arbor, Michigan 481090378, United States
  • Washington Univ School of Medicine
    St Louis, Missouri 63108, United States
  • Univ of Nebraska Medical Ctr
    Omaha, Nebraska 681985400, United States
  • Robert Wood Johnson Med School/UMDNJ
    New Brunswick, New Jersey 089030019, United States
  • UMDNJ - New Jersey Med School
    Newark, New Jersey 071032757, United States
  • ID Care Inc
    Somerville, New Jersey 08876, United States
  • Univ of NM
    Albuquerque, New Mexico 87131, United States
  • Duke Univ Med Ctr / Infectious Disease Clinic
    Durham, North Carolina 27710, United States
  • Jemsek Clinic
    Huntersville, North Carolina 28078, United States
  • Ohio State Univ Hosp
    Columbus, Ohio 432101282, United States
  • Philadelphia FIGHT
    Philadelphia, Pennsylvania 19107, United States
  • Julio Arroyo
    West Columbia, South Carolina 29169, United States
  • Methodist Healthcare
    Memphis, Tennessee 38104, United States
  • Oaklawn Physicians Group
    Dallas, Texas 75219, United States
  • Tarrant County Infectious Diseases Associates
    Fort Worth, Texas 76104, United States
  • Montrose Clinic
    Houston, Texas 77006, United States
  • AKH Wien
    Wien, Austria
  • Pulmologisches Zentrum Der Stadt Wien
    Wien, Austria
  • CHU Saint Pierre
    Brussels, Belgium
  • UZ Gasthuisberg
    Leuven, Belgium
  • Univ of Alberta/Division of Inf Dis/Dept of Med
    Edmonton, Alberta, Canada
  • Univ of British Columbia
    Vancouver, British Columbia, Canada
  • McMaster Univ Med Ctr
    Hamilton, Ontario, Canada
  • Gary Rubin
    Toronto, Ontario, Canada
  • Fundacion Arriaran
    Santiago, Chile
  • Hosp Clinico de La Pontificia Universidad Catolica de Chile
    Santiago, Chile
  • Hosp Sotero de Rio
    Santiago, Chile
  • Servicio de Dermatologia-Hosp del Salvador
    Santiago, Chile
  • SEMECO
    San Jose, Costa Rica
  • Hopital Hotel Dieu de Lyon
    Lyon, France
  • Services des Maladies Infectieuses
    Paris Cedex 12, France
  • CHU De Bicetre
    Paris, France
  • Hopital Cochin - Port Royal
    Paris, France
  • Hospital Gustave Dron
    Tourcoing, France
  • Rheinische Friedrich Wilhelms Universitaet Medizinische
    Bonn, Germany
  • Univ Zu Koeln
    Koeln, Germany
  • Hosp General San Juan de Dios
    Guatemala, Guatemala
  • Hosp Roosevelt Chief Infectious Diseases Unit
    Guatemala, Guatemala
  • Saint Laszlo Hosp
    Budapest, Hungary
  • Kaplan Med Ctr
    Rehovot, Israel
  • Ospedale S Orsola
    Bologna, Italy
  • Immunoligia Universita Cagliari
    Cagliari, Italy
  • Ospedale Luigi Sacco Cargnel
    Milano, Italy
  • Ospedale S Raffaele
    Milano, Italy
  • Ospedale degli Infermi
    Rimini, Italy
  • Cat All Immun Clin
    Roma, Italy
  • Ospedale Amedeo de Savoia
    Torino, Italy
  • Ospedale Amedeo di Savoia
    Torino, Italy
  • Hosp Kuala Lumpur
    Kuala Lumpur, Malaysia
  • Univ of Malaya Med Ctr
    Kuala Lumpur, Malaysia
  • Consultorio Royal Ctr
    Panama, Panama
  • Hosp Edgardo Rebagliati
    Lima, Peru
  • Hosp Guillermo Almenara-Medicina 1
    Lima, Peru
  • Hosp Nacional Arzobispo Loayza-PROCETS
    Lima, Peru
  • Hosp Nacional Cayetano Heredia
    Lima, Peru
  • Hosp Nacional dos de Mayo
    Lima, Peru
  • Hosp De Santa Maria
    Lisboa, Portugal
  • Hosp De Sao Joao
    Porto, Portugal
  • Clinical Research Puerto Rico Inc
    San Juan, 009091711, Puerto Rico
  • San Juan VAMC
    San Juan, 009265800, Puerto Rico
  • Federal AIDS Ctr
    Moscow, Russian Federation
  • Infectious Hosp 30
    St Petersburg, Russian Federation
  • Ust Izhora Fed Infectious Hosp
    St Petersburg, Russian Federation
  • Brooklyn Med Ctr
    Cape Town, South Africa
  • Tygerberg Hosp
    Cape Town, South Africa
  • Chris Hani Baragwanath Hosp
    Johannesburg, South Africa
  • Toga Lab
    Johannesburg, South Africa
  • Hosp Clinic
    Barcelona, Spain
  • Hosp Germans Trias I Pujol
    Barcelona, Spain
  • Hosp de Basurto / Enfermedades Infecciosas
    Bilboa, Spain
  • Hosp Reina Sofia
    Cordoba, Spain
  • Hosp Carlos III
    Madrid, Spain
  • Hosp Ramon y Cajal
    Madris, Spain
  • Hosp Nuestra Senora de Covadonga
    Oviedo, Spain
  • Hosp Virgen Del Rocio
    Sevilla, Spain
  • Universitatsspital Zurich
    Zurich, Switzerland
  • Rajavithi Hosp
    Bangkok, Thailand
  • Ramathibodi Hosp
    Bangkok, Thailand
  • Siriraj Hosp / Mahidol Univ
    Bangkok, Thailand
  • Vajira Hosp
    Bangkok, Thailand
  • Chiangmai Univ
    Chiang Mai, Thailand
  • King's College Hosp
    Cambewell, United Kingdom
  • Saint James Hosp
    Dublin, United Kingdom
  • Royal Free Hosp
    London, United Kingdom
  • Hosp U de Caracas / Ciudad
    Caracas, Venezuela
  • Hosp Vargas de Caracas
    Caracas, Venezuela
  • Hosp Dr Domingo Luciani
    Miranda, Venezuela
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2001, a primary completion of Apr 2003 and a completion of Apr 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2001
First posted
Aug 31, 2001
Start
Feb 2001
Primary completionActual
Apr 2003
CompletionActual
Apr 2003
Results delay requested
Apr 13, 2011
Last update
May 4, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00013897
First posted
Aug 31, 2001
Start date
Feb 2001
Primary completion
Apr 2003
Completion
Apr 2003
Last update
May 4, 2011
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lamivudine · Zidovudine · Efavirenz

Start the discussion